ArticlePloS one2015
Declining incidence of candidemia and the shifting epidemiology of Candida resistance in two US metropolitan areas, 2008-2013: results from population-based surveillance.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 144 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
144 citing papers in PubMed, 1 synthesis or guideline pooled it, 303 citations in OpenAlex.
- [S3 guideline on sepsis-prevention, diagnosis, therapy, and follow-up care-update 2025].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2025Guideline
- Contemporary Trends in Candidemia: Mortality, Species, and Antifungal Resistance Across Three Periods (2017-2025) in Houston, Texas.Open forum infectious diseases · 2026Article
- Article
- Epidemiology of source-related candidaemia and breakthrough candidaemia in intensive care units.BMC infectious diseases · 2026Article
- Ten-Year Trends in Candidemia at a Tertiary-Care Hospital in Spain (2015-2024): Epidemiological Shifts, Diagnostic Acceleration, and Impact of Antifungal Stewardship in the COVID-19 and Post-Pandemic Era.Journal of fungi (Basel, Switzerland) · 2026Article
- Candida albicans infection suppresses lipopolysaccharide or Pseudomonas aeruginosa stimulated murine bone marrow derived macrophage (BMDM) responses.Scientific reports · 2026Article
- Incidence Rates of Candida Bloodstream Infections in Patients With Malignancies in a Comprehensive Cancer Centre.Mycoses · 2025Article
- Article
- Heterogeneity ofMicrobiology spectrum · 2025Article
- Yeast fungaemia among injection drug users in France (2012-2022): a cross-sectional observational study.The Lancet regional health. Europe · 2025Article
- Clinical and Molecular Epidemiological Characteristics of 26 Bloodstream Infection Cases Caused by Candida tropicalis.Mycopathologia · 2025Article
- Trends in Candidemia Over the Last 14 Years: A Comparative Analysis ofOpen forum infectious diseases · 2025Article
- Population-Based Active Surveillance for Culture-Confirmed Candidemia - 10 Sites, United States, 2017-2021.Morbidity and mortality weekly report. Surveillance summaries (Washington, D.C. : 2002) · 2025Article
- Creating a prediction model for invasive candidiasis in the intensive care unit using a case control design: a European multicentre approach.BMC infectious diseases · 2025Article
- Biofilm-Associated Candidiasis: Pathogenesis, Prevalence, Challenges and Therapeutic Options.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Antimicrobial Activity of the Peptide C14R Against Ab Initio Growing and Preformed Biofilms ofBiomolecules · 2025Article
- Effects of Ire1 gene on virulence and pathogenicity ofOpen life sciences · 2025Article
- Trends inMycobiology · 2025Article
- Understanding adaptation to fluconazole: comparative insights into tolerance and resistance inFrontiers in cellular and infection microbiology · 2025Article
- Managing Invasive Fungal Infections During Allogeneic Hematopoietic Transplantation: A 2025 Update.Mediterranean journal of hematology and infectious diseases · 2025Review
84 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecent reports have demonstrated a decline in bacterial bloodstream infections (BSIs) following adherence to central line insertion practices; however, declines have been less evident for BSIs due to Candida species.
methodsWe conducted active, population-based laboratory surveillance for candidemia in metropolitan Atlanta, GA and Baltimore, MD over a 5-year period. We calculated annual candidemia incidence and antifungal drug resistance rates.
resultsWe identified 3,848 candidemia cases from 2008-2013. Compared with 2008, candidemia incidence per 100,000 person-years decreased significantly by 2013 in both locations (GA: 14.1 to 9.5, p<0.001; MD: 30.9 to 14.4, p<0.001). A total of 3,255 cases (85%) had a central venous catheter (CVC) in place within 2 days before the BSI culture date. In both locations, the number of CVC-associated cases declined (GA: 473 to 294; MD: 384 to 151). Candida albicans (CA, 36%) and Candida glabrata (CG, 27%) were the most common species recovered. In both locations, the proportion of cases with fluconazole resistance decreased (GA: 8.0% to 7.1%, -10%; MD: 6.6% to 4.9%, -25%), while the proportion of cases with an isolate resistant to an echinocandin increased (GA: 1.2% to 2.9%, +147%; MD: 2.0% to 3.5%, +77%). Most (74%) echinocandin-resistant isolates were CG; 17 (<1%) isolates were resistant to both drug categories (multidrug resistant [MDR], 16/17 were CG). The proportion of CG cases with MDR Candida increased from 1.8% to 2.6%.
conclusionsWe observed a significant decline in the incidence of candidemia over a five-year period, and increases in echinocandin-resistant and MDR Candida. Efforts to strengthen infection control practices may be preventing candidemia among high-risk patients. Further surveillance for resistant Candida is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.